Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2019-08-14 Board/Management Inform…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Jon Johnsson appointed new CFO of Karo Pharma
Board/Management Information Classification · 99% confidence The document text is a press release announcing a specific change in senior management: the appointment of Jon Johnsson as the new CFO and the retirement of the previous CFO. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2019-08-14 English
Jon Johnsson utsedd till ny CFO på Karo Pharma
Board/Management Information Classification · 98% confidence The document text is a short announcement in Swedish detailing the appointment of a new Chief Financial Officer (CFO), Jon Johnsson, replacing the retiring CFO, Mats-Olof Wallin, at Karo Pharma. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (1863 chars), but it is the primary announcement itself, not a notice about another report, so RPA/RNS is not the primary fit. Therefore, MANG is the most appropriate classification.
2019-08-14 Swedish
Förtydligande avseende skrivning om företrädesemissionen i delårsrapporten som publicerades den 19 juli 2019
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 19, 2019, titled "Clarification regarding the subscription rights issue in the interim report published on July 19, 2019." It explicitly states that the company ("Karo Pharma") today published its interim report for January to June 2019, and this press release serves to clarify a misleading statement within that report regarding a rights issue (a capital/financing activity). Since the document's primary function is to announce the publication of a report (the interim report) and immediately clarify a detail within it, it strongly aligns with the definition of a Report Publication Announcement (RPA). Although it discusses capital structure (rights issue), the immediate context is the announcement/clarification related to the release of the interim report. Given the short length (1447 chars) and the nature of clarifying a recently published report, RPA is the most appropriate classification over IR (Interim Report) or CAP (Capital/Financing Update).
2019-07-19 Swedish
Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 19, 2019, specifically titled 'Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights.' It clarifies details about a planned rights issue (a capital/financing activity) that was mentioned in the interim report. Since the document's primary purpose is to correct or clarify information related to a financing event (rights issue), it strongly aligns with the Capital/Financing Update (CAP) category. Although it mentions the interim report, the core subject is the financing structure clarification, not the full interim financial report itself. Given the short length (1534 chars) and the nature of the announcement, CAP is the most specific fit over a general RPA or RNS.
2019-07-19 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI – JUNI 2019' (Interim Report January-June 2019). It contains comprehensive financial statements, management commentary, key performance indicators, and risk disclosures for the specified period. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. H2 2019
2019-07-19 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – JUNE 2019' and contains comprehensive financial statements, including consolidated income statements, cash flow data, and management commentary on operations, risks, and significant events. It covers a period shorter than a full fiscal year (six months), fitting the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full financial data and analysis. H1 2019
2019-07-19 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.